Comparison Between a Toric Monofocal and Multifocal Intraocular Lens
Launched by BEAVER-VISITEC INTERNATIONAL, INC. · May 25, 2021
Trial Information
Current as of May 08, 2025
Completed
Keywords
ClinConnect Summary
This retrospective study will include approximately 90 eyes of patients (adults) receiving conventional cataract surgery having a preoperative corneal astigmatism of 1.0 D or higher. They had been implanted with the Ankoris or T-Flex or FineVision toric implant (about 30/30 and20). So that the groups are comparable, the inclusion and exclusion criteria will be those applicable to a multifocal implant.
Inclusion criteria for research participants.
* Cataract (with or without presbyopia)
* No pre-existing ocular pathology or history of ocular surgery
* No phacodonesis
PEX patients (pseudoe...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Cataract (with or without presbyopia)
- • No pre-existing ocular pathology or history of ocular surgery
- • No phacodonesis
- • PEX patients (pseudoexfoliation syndrome) can be included.
- Exclusion Criteria:
- • To ensure equivalence of the two comparable groups, the patients with potential postoperative visual acuity less than 5/10, particularly due to an insufficient retinal function or poor corneal condition will be excluded.
- In particular the patients with the following pathologies will be excluded:
- • Irregular astigmatism.
- • Cases of uncontrolled glaucoma.
- • Intraocular inflammation.
- • Narrow anterior chambers (2.5 mm).
- • Amblyopia with potential visual acuity less than 5/10.
- • Any corneal pathology potentially affecting topography (e.g., keratoconus).
- • Patients with a history of corneal surgery (especially refractive surgery).
- • Patients with diagnosed degenerative visual disorders (e.g., macular degeneration, diabetic retinopathy or other retina diseases or surgery) with known negative impact on visual function possibly leading to visual acuity levels below 0.5.
- • Patients with a history of ocular trauma.
- • Pathological miosis.
- • Patients with zonular laxity.
- • Patients suffering from chronic uveitis.
- • Patients with monophthalmia. Capsule rupture, intraocular haemorrhage, excessive loss of vitreous, vitreous flare, soft capsules during cataract surgery are also exclusion criteria.
About Beaver Visitec International, Inc.
Beaver-Visitec International, Inc. is a leading global medical device company specializing in innovative surgical solutions for ophthalmic and other medical specialties. With a commitment to advancing patient care, the company focuses on developing high-quality, innovative products that enhance surgical precision and improve clinical outcomes. Leveraging extensive research and development expertise, Beaver-Visitec collaborates with healthcare professionals to address unmet needs in the operating room, thereby transforming surgical practices and enhancing patient safety. Through its dedication to excellence and innovation, Beaver-Visitec continues to play a pivotal role in the evolution of surgical technologies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Visp, , Switzerland
Patients applied
Trial Officials
Kristof Vandekerckhove, MD
Principal Investigator
Vista Alpina Eye Cente, Visp, Switzerland, 3930
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials